The GRADE trial suggested no difference in cognitive decline across insulin glargine, the DPP4 inhibitor sitagliptin, the sulfonylurea glimepiride, and the GLP1 receptor agonist liraglutide, but the mean age was 57.1 years, and SGLT2 inhibitors were not examined [54]. Here, SLC5A2 is linked to Mental deterioration.